Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl…
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to…
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics,…
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
March 20, 2026 16:30 ET | Source: Zevra Therapeutics BOSTON, March 20,…
Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics
The Atlas will expand known evolutionary genetic diversity by 100x, collecting novel…
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
March 17, 2026 22:46 ET | Source: CytomX Therapeutics Inc. SOUTH SAN…
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026 17:33 ET | Source: Tango Therapeutics Sub, Inc BOSTON,…
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
March 06, 2026 18:15 ET | Source: Lisata Therapeutics, Inc. Each Lisata…
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Presented positive updated data from the ALLOHA™ Phase 1 heme trial at…
Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing
Chesterbrook, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”),…
